Kurzfassung

A phase II, cohort, open-label, multicenter, global study designed to assess the efficacy, safety and tolerability of Atezolizumab administered in combination with Obinutuzumab or Rituximab to patients with refractory or relapsed Mantle Cell Lymphoma (MCL), Marginal Zone lymphoma (MZL) and Waldenström Macroglobulinemia (WM).